Among adolescents and young adults, cTnI levels remain within normal ranges after mRNA-1273 vaccination, with no evidence of increased myocardial injury.

Neal Browning pushed this story back into view with a short social media post. Newsweek said he marked the 6-year anniversary of Moderna's first human trial. He described his "side effects" with ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

Get any of our free daily email newsletters — news headlines, opinion, e-edition, obituaries and more. My wife and I are agreed, news likely to impact us directly at age 86 is the only news to which ...

Have you seen ads for the new low-dose COVID vaccine called mNEXSpike and wondered what it's all about? Us too! So we did some digging-and spoke to University of California-Irvine immunization expert ...

A new study led by the Centenary Institute and the University of Sydney shows that a nasal vaccine could offer powerful protection against COVID-19. It works by stopping infection in the nose before ...

The U.S. death toll from the coronavirus topped 300,000 Monday just as the country began dispensing COVID-19 shots in a monumental campaign to conquer the outbreak. The number of dead rivals the ...

The COVAX programme has signed deals for hundreds of millions of doses to vaccinate people in poor and lower-middle income ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...